Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • No longer available  
  • Page 1 ·  Next »

NCT ID: NCT05541289 No longer available - COVID-19 Clinical Trials

Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older

Start date: n/a
Phase:
Study type: Expanded Access

This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization options against SAR-CoV-2 Virus infection.

NCT ID: NCT05235347 No longer available - Covid19 Clinical Trials

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

NCT ID: NCT04802083 No longer available - Covid19 Clinical Trials

COVID-19 Soliris Expanded Access Protocol

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides participants with COVID-19 access to Soliris.

NCT ID: NCT04798066 No longer available - Clinical trials for Post COVID-19 Syndrome

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.

NCT ID: NCT04636554 No longer available - Covid19 Clinical Trials

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Start date: n/a
Phase:
Study type: Expanded Access

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

NCT ID: NCT04603651 No longer available - COVID-19 Clinical Trials

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT04597242 No longer available - Covid19 Clinical Trials

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI), including right-sided endocarditis (R-IE), who are hospitalized with coronavirus disease 2019 (COVID-19). Patients with left-sided endocarditis (L-IE) are excluded. Patients will receive a single dose of exebacase. Patients will continue to receive antistaphylococcal antibiotics as prescribed by the treating physician. Exebacase Phase 3 study sites (Study CF-301-105) may participate in this Expanded Access study (Study CF-301-107). Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to standard-of-care antibiotics to treat S. aureus BSI including IE.

NCT ID: NCT04476706 No longer available - Clinical trials for Cytokine Release Syndrome in COVID-19-induced Pneumonia

Canakinumab MAP in COVID-19 Pneumonia With CRS

Start date: n/a
Phase:
Study type: Expanded Access

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

NCT ID: NCT04472572 No longer available - COVID-19 Clinical Trials

Expanded Access to Convalescent Plasma for Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

NCT ID: NCT04453839 No longer available - Clinical trials for Critical COVID-19 With Respiratory Failure

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

SAMICARE
Start date: n/a
Phase:
Study type: Expanded Access

Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor. Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization. Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download